Literature DB >> 194153

Adherence of human peripheral blood lymphycytes to measles-infected cells. Enhancement by prostaglandin E1.

R B Zurier, P Dore-Duffy, M V Viola.   

Abstract

We studied the effect of prostaglandins in vitro on an immune reaction mediated by T cells; adherence of lymphocytes to measles-virus-infected human epithelial cells. Normal human lymphocytes adhered to a mean +/- S.D. 20.1 +/- 5.2 per cent of these HEp-2 cells. The percentage positive cells increased to 50.3 +/- 5.7 when lymphocytes were incubated with 10(-6) M prostaglandin E1 (P less than 0.01 vs. untreated lymphocytes); 10(-8) M and 10(-10) M were as effective. Prostaglandin F2alpha had no effect on lymphocyte adherence. Prostaglandin E1 increased lymphocyte cyclic AMP five to 10 times whereas prostagladin F2alpha did not affect cellular levels of this nucleotide. Dibutyryl cyclic AMP (10(-8) M) increased lymphocyte adherence: positive human epithelial cells increased from 16.0 +/- 2.4 to 38.7 +/- 1.1 per cent (P less than 0.01). Prostagladin E1 also increased adherence of lymphocytes from patients with systemic lupus erythematosus from 21.8 +/- 5.8 to 52.5 +/- 9.2 per cent (P less than 0.01). These results indicate that prostagladin E1 and cyclic AMP may serve to stimulate T-cell function and cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 194153     DOI: 10.1056/NEJM197706232962506

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  3 in total

Review 1.  The role of prostaglandins in altered leukocyte function in multiple sclerosis.

Authors:  P Dore-Duffy; S Y Ho; M Longo
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Lymphocyte adherence in multiple sclerosis: effect of aspirin.

Authors:  P Dore-Duffy; R B Zurier
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

3.  Lymphocyte adherence to myelinated tissue in multiple sclerosis.

Authors:  P Dore-Duffy; V Goertz; B L Rothman
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.